Ibrutinib skin toxicities: report of two cases.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of cutaneous pathology"
DOI: 10.1111/cup.14160
Abstract: Ibrutinib is a Bruton tyrosine kinase inhibitor used to treat many hematologic conditions, most commonly B-cell lymphomas and leukemias. Reportedly, skin rash is an adverse event in up to 27% of treated patients. Histopathologic description… read more here.
Keywords: toxicities report; report two; cases ibrutinib; ibrutinib skin ... See more keywords